Fluvoxamine Offers Hope for Long COVID Fatigue | Science News

A breakthrough for long COVID sufferers: fluvoxamine, a common antidepressant, has shown remarkable promise in slashing debilitating fatigue and boosting quality of life in a global trial. With a 99% chance of outperforming placebo, this widely available drug could offer real relief where few treatments exist — and its adaptive trial design may speed up access for those desperately in need. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ccb127cb79291e10